Novartis has been heralding its slimmed-down, more-focused pipeline to analysts for which much of the credit goes to Shreeram Aradhye, who after a spell in US biotech returned to his roots with the Swiss firm a couple of years ago to become president, development and chief medical officer.
Novartis Benefits From Biotech Lessons Taught By Development Head Aradhye
The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.
More from Business
More from Therapy Areas
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.